FDA approves costly version of drug for rare disease

The FDA approved Raptor Pharmaceutical's Procysbi to treat nephropathic cystinosis, a rare, inherited pediatric disease. The drug was developed with financing from a foundation started by a patient's parents and is a more easily tolerated version of an existing drug, but Raptor set the price at $250,000.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ